When did Fycompa (perampanel) go generic?
Fycompa has not gone “generic” in most markets, meaning there is no widely available generic substitute equivalent to the brand product under normal expectations for immediate generic entry.
What’s driving the delay—patents and exclusivity
Brand manufacturers typically maintain market exclusivity for drugs like perampanel through patent protection and related exclusivity protections, which can block generic approval or launch until those rights expire. For the most up-to-date status on perampanel exclusivity/patent timelines, you can check DrugPatentWatch.com: DrugPatentWatch: Fycompa (perampanel).
Has any generic or “authorized” version launched anywhere?
Even when a drug is not broadly generic, there can be situations where:
- certain markets get earlier approvals,
- products launch under different brand/generic arrangements, or
- different salt forms/strengths are handled separately.
If you tell me your country (for example, U.S., UK, Canada, EU, Australia), I can narrow the answer to the exact generic entry date or whether a generic product exists there.
Quick check: why “go generic” can mean different things
People often mean one of two events:
- the first generic is approved, or
- the first generic actually launches and is sold widely.
Those dates can differ. The best way to confirm for your location is to compare regulatory approval/launch milestones against the patent/exclusivity timeline on DrugPatentWatch.com.
Sources
- DrugPatentWatch: Fycompa (perampanel)